
Featured Product
Palbociclib and ribociclib key intermediates and API
Oral CDK4/6 — take the listed building blocks, API, or both, for either molecule or both programs.
- CDK4/6
- Oral
- Key intermediates
- API
Key intermediates
A palbociclib core scaffold plus a protected aminopyridyl-piperazine side chain shared with ribociclib.
- CAS 1016636-76-2 and 571188-59-5 listed
- Assay, regioisomers, residual starting materials and reaction-related impurities named in the spec
Active pharmaceutical ingredient
Palbociclib and ribociclib API for breast-cancer generic-development programs.
- Coupling performance starts with the listed heterocyclic blocks
- Downstream purification and manufacturing efficiency named in the program plan
Building blocks listed
A key palbociclib scaffold intermediate and a shared building block used on palbociclib and ribociclib routes. Tell us which numbers you need and the volume range.
1016636-76-2
571188-59-5
Originator programs — not Unibest branded products
CDK0/6
Oral inhibitors in breast cancer (originator brands: Ibrance, Kisqali)
Industry context
Palbociclib and ribociclib are commercially validated oral CDK4/6 inhibitors with established and expanding applications in breast cancer treatment. That is why a core heterocyclic scaffold, a shared side-chain building block and API need a commercial-ready supply — not a research-only catalogue.
For manufacturers and marketers
01Marketing-authorisation holders
02Regional manufacturers
03Distributors
Not a consumer offer, and not originator-branded product.
Why this supply
The core scaffold and the protected side chain are listed separately, so generic API work can be scoped to the molecule and the step you are running.
Palbociclib scaffold intermediate
6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one (CAS 1016636-76-2) is a key palbociclib scaffold intermediate.
Shared side-chain building block
tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate (CAS 571188-59-5) is a protected aminopyridyl-piperazine building block applicable to palbociclib and ribociclib routes.
Regioisomers and residual starting materials
Consistent control of assay, regioisomeric impurities, residual starting materials and reaction-related impurities can improve coupling performance.
Purification and manufacturing efficiency
That same control supports downstream purification and overall API manufacturing efficiency. We quote against specification and volume — not a list price on this page.
How a program starts
Same sequence whether you take listed building blocks, API, or both — and whether you start with one molecule or both.
- 01
Scope
Which molecule, which CAS numbers, grade, volume and whether you need intermediates, API, or both. We confirm what we can stand behind before work starts.
- 02
Align the file
Specification, CoA format, regioisomers, residual starting materials and reaction-related impurities — written down while gaps are still cheap to close.
- 03
Qualify supply
Listed lots and/or commercial API against that spec. Audit findings stay in the same program plan.
- 04
Deliver and hold
First shipment, then change control from one owner.
Frequently asked
Ready to scope a supply?
Send the molecule, grade and a volume range. We reply with what we can stand behind.